A 12-week, multicenter, randomized, double-blind, placebo-controlled, parallel group, dose-finding study to evaluate the efficacy, safety, and tolerability of ACZ885 (anti-interleukin-1 beta monoclona...

Mise à jour : Il y a 5 ans
Référence : EUCTR2006-001550-27

A 12-week, multicenter, randomized, double-blind, placebo-controlled, parallel group, dose-finding study to evaluate the efficacy, safety, and tolerability of ACZ885 (anti-interleukin-1 beta monoclonal antibody) with three different dose regimens in patients with active rheumatoid arthritis despite stable treatment with methotrexate

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To assess the efficacy of three dose regimens of ACZ885 ( (1) 600 mg i.v. loading dose plus 300 mg s.c. q2wk, (2) 300 mg s.c. q2wk, (3) 150 mg s.c. q4wk) compared to placebo as add-on treatment in patients with active RA despite stable treatment of MTX at the maximum tolerated dose (<_ 25 mg/week) for at least 12 weeks, by assessing the response to treatment (ACR50 criteria) after 12 weeks.


Critère d'inclusion

  • active rheumatoid arthritis